In vitro and in vivo evaluation of PEGylated nanoparticles of bendamustine for treatment of lung cancer

References

• Chen J, Li S, Shen Q, He H, Zhang Y. 2011. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug Dev Ind Pharm. 37:1339–1346.
   PubMed Web of Science ®Google Scholar
• Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, Preat V. 2009. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Control Release 133:11–17.
   PubMed Web of Science ®Google Scholar
• Gandhi V. 2002. Metabolism of mechanism of action of bendamustine rationales for combination therapies. Semin Oncol. (4 Supp 13): 4–11.
   PubMed Web of Science ®Google Scholar
• Gao JQ, Eto Y, Yoshioka Y, Sekiguchi F, Kurachi S, Morishige T. 2007. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release. 122:102–110.
   PubMed Web of Science ®Google Scholar
• Gidwani B, Vyas A. 2014. Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment. Pharm Dev Technol. 1–11.
   Google Scholar
• Gupta A, Kaur CD, Saraf S, Saraf S. 2015. Formulation, characterization, and evaluation of ligand-conjugated biodegradable quercetin nanoparticles for active targeting. Artif Cells Nanomed Biotechnol. (doi:https://doi.org/10.3109/21691401.2015.1008503).
   Google Scholar
• Jiang X, Dai H, Leong KW, Goh SH, Mao HQ, Yang YY. 2006. Chitosan-g-PEG/DNA complexes deliver gene to the rat liver via intrabiliary and intraportal infusions. J Gene Med. 8:477–487.
   PubMed Web of Science ®Google Scholar
• Luo F, Li Y, Jia M, Cui F, Wu H, Yu F, Lin J, Yang X. 2014. Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro. Nanoscale Res Lett. 9:363.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. 2005. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 107:215–228.
   PubMed Web of Science ®Google Scholar
• Mu L, Feng S.S. 2003. A novel controlled release formulation for the anticancer drug Paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 86:33–48.
   PubMed Web of Science ®Google Scholar
• Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, et al. 2009. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine. 5:184–191.
   PubMed Web of Science ®Google Scholar
• Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM. 2009. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 5:410–418.
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y. 2004. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res. 10:8293–8300.
   PubMed Web of Science ®Google Scholar
• Tabatabaei Mirakabad FS, Akbarzadeh A, Milani M, Zarghami N, Taheri-Anganeh M, Zeighamian V, et al. 2015. A Comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif Cell Nanomed Biotechnol. (doi: https://doi.org/10.3109/21691401.2014.955108).
   Google Scholar
• Terada T, Mizobata M, Kawakami S, Yamashita F, Hashida M. 2007. Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release. 119:262–270.
   PubMed Web of Science ®Google Scholar
• Travis WD, Travis LB, Devesa SS. 1995. Lung cancer incidence and survival by histological type. Lung Canc. 75:191–202.
   Google Scholar
• Tsutsumi Y, Tsunoda S, Kaneda Y, Kamada H, Kihira T, Nakagawa S, et al. 1996. In vivo anti-tumor efficacy of polyethylene glycol- modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors. Jpn J Canc Res. 87:1078–1085.
   PubMedGoogle Scholar
• United States, National Institutes of Health, Cancer Therapy Evaluation Program (ctep). 2011. Common Toxicity Criteria (CTC).
   Google Scholar
• WHO, Disease and injury country estimates. 2009. WHO fact sheet on cancer.
   Google Scholar
• Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang YH. 2004. Camptothecin derivative loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release. 96:135–148.
   PubMed Web of Science ®Google Scholar